{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"Extended spectrum beta lactamase testing: Audrey Schuetz, M.D.","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/951e3ebb\"></iframe>","width":"100%","height":180,"duration":524,"description":"Clinical microbiologist and pathologist Audrey Schuetz, M.D., discusses Mayo Clinic Laboratories’ new culture-based extended spectrum beta lactamase (ESBL) testing that screens for the presence of multi-drug resistant gram-negative bacteria in donor stool intended for fecal microbiota transplantation. The screening test is performed on stool or swab samples taken from around the anus and is used to detect the colonization or carriage of ESBL bacteria that could jeopardize the outcomes of fecal microbiota transplants, especially in patients who carry ESBL bacteria in their gut without getting sick. ","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}